In this study, the A2AR antagonist KW6002, a drug already in clinical phase III trials for Parkinson’s disease treatment with noted safety profile for aging population (Chen et al. 2013), was used to demonstrate the efficacy and selectivity of A2AR antagonist control of ROP without affecting normal retinal vascular development. Here, ADORA2A is linked to retinopathy of prematurity.